Psychemedics Corporation Announces Third Quarter Profits

Drug News, Press Releases

Acton, Massachusetts, November 3, 2011 — Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2011. The Company also announced a quarterly dividend of $0.12 per share payable to shareholders of record as of November 17, 2011 to be paid on December 1, 2011. This will be the Company’s 61st consecutive quarterly dividend.

The Company’s revenue for the quarter ended September 30, 2011 was $6.3 million versus $5.1 million for the quarter ended September 30, 2010, an increase of 24%. Net income for the quarter ended September 30, 2011 was $1.1 million or $0.21 per diluted share, versus $817 thousand or $0.16 per diluted share, for the comparable period last year, an increase of 35%. The Company’s revenue for the nine months ended September 30, 2011 was $18.5 million, as compared to $15.0 million for the comparable period of 2010, an increase of 24%. Net income for the nine months ended September 30, 2011 was $3.1 million or $0.58 per diluted share, as compared to last year during which the Company earned $2.2 million or $0.42 per diluted share, an increase of 39%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,
“Our third quarter results were strong, both on the top line as well as earnings. The majority of our growth came from new business. However, in light of the current tepid economic environment, we were also encouraged to see growth in our base business. We continued to have robust margins including a 29% pre-tax margin. While we maintained tight cost control, we also continue to make investments in sales and marketing.

“Our balance sheet remained strong with no long-term debt and cash of $3.5 million. There was a temporary increase in accounts receivable and corresponding reduction of cash from prior quarters due to a delay in August invoicing as a result of a one-time upgrade to our billing system.

“Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward.

“Therefore, the Board has declared a $0.12 dividend for the quarter. This is our 61st consecutive quarterly dividend. In addition, we continue to have a share buyback program in place.”

Psychemedics is the world’s largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics’ clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

The Psychemedics web site is www.psychemedics.com

Menu